Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Michaël Harnois"'
Autor:
Eliane Nguyen, Michaël Harnois, Lambert Busque, Shireen Sirhan, Sarit Assouline, Ines Chamaki, Harold Olney, Luigina Mollica, Natasha Szuber
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-6 (2021)
Externí odkaz:
https://doaj.org/article/3d748657e5de4035a978655d909e9f1e
Autor:
Adi J. Klil-Drori, Hui Yin, Laurent Azoulay, Michaël Harnois, Michel-Olivier Gratton, Lambert Busque, Sarit E. Assouline
Publikováno v:
Haematologica, Vol 104, Iss 7 (2019)
Externí odkaz:
https://doaj.org/article/2a2ce2466efd412eae2c44ee54ee3d63
Autor:
Sarit Assouline, Eliane Nguyen, Harold J. Olney, Natasha Szuber, Ines Chamaki, Michaël Harnois, Lambert Busque, Shireen Sirhan, Luigina Mollica
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Autor:
Eliane Nguyen, Sarit Assouline, Harold J. Olney, Natasha Szuber, Michaël Harnois, Ines Chamakhi, Luigina Mollica, Lambert Busque, Shireen Sirhan
Publikováno v:
Blood. 136:4-7
Background: Since lowering the hemoglobin (Hb) and hematocrit (Hct) diagnostic thresholds for polycythemia vera (PV) to 165 g/L and 49% in men and 160 g/L and 48% in women respectively, by the World Health Organization (WHO) in 2016 (Blood. 2016;127:
Autor:
Lambert Busque, Kevin Simpson-Poirier, Michel-Olivier Gratton, Robert Delage, Luigina Mollica, Harold J. Olney, Shireen Sirhan, Pierre Laneuville, Michaël Harnois, Sarit Assouline, Natasha Szuber
Publikováno v:
American Journal of Hematology. 96
Publikováno v:
Blood. 138:3650-3650
Background: The median age at diagnosis of myeloproliferative neoplasms (MPN) is in the sixth decade, though adolescents and young adults (AYA) with MPN comprise a distinct, growing sub-population. Preliminary data has exposed a unique phenotype and
Autor:
Michaël Harnois, Natasha Szuber, Judith Jolin, Shireen Sirhan, Pierre Laneuville, Robert Delage, Harold J. Olney, Lambert Busque, Luigina Mollica
Publikováno v:
Blood. 138:2572-2572
Background and methods: Increasing life expectancy has had the impact of increasing the proportion of patients with myeloproliferative neoplasms (MPN) aged ≥75 years (very elderly patients; VEP). However, few studies have evaluated the phenotype an
Publikováno v:
Blood. 138:4602-4602
Introduction: Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) widely used for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML). ENESTnd, which compared two doses of nilotinib to imatinib for p
Autor:
Pierre Laneuville, Hui Yin, Laurent Azoulay, Michaël Harnois, Robert Delage, Lambert Busque, Harold J. Olney, Luigina Mollica, Alexa Del Corpo, Michel-Olivier Gratton, Sarit Assouline, Adi J. Klil-Drori
Publikováno v:
Cancer. 125(4)
BACKGROUND In the current study, the authors determined whether adhering to molecular monitoring guidelines in patients with chronic myeloid leukemia (CML) is associated with major molecular response (MMR) and assessed barriers to adherent monitoring